 |
|
|
| |
Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients
|
| |
| |
Reported by Jules Levin
AASLD Nov 1-5 2013 Wash DC
Kosh Agarwal,1 Scott K. Fung,2 Tuan T. Nguyen,3 Wendy Cheng,4 Eric Sicard,5 Stephen D. Ryder,6 John F. Flaherty,7 Eileen Lawson,7
Sally Zhao,7 Mani Subramanian,7 John G. McHutchison,7 Edward J. Gane,8 Graham R. Foster9
1Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 2Toronto General Hospital, Toronto, Ontario, Canada; 3T. Nguyen Research and Education, San Diego, CA; 4Royal Perth Hospital, Perth, Western Australia, Australia; 5Algorithme Pharma, Montreal, Quebec, Canada;
6Nottingham University Hospitals NHS Trust and Biomedical Research Unit, Nottingham, United Kingdom; 7Gilead Sciences, Inc., Foster City, CA; 8Auckland Clinical Studies, Auckland, New Zealand; 9Queen Mary's University of London, Barts Health, United Kingdom
|
| |
|
|
|
|
|
